Sanofi : MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers
MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers July 10, 2021 Results from a head-to-head Phase 3 study, evaluating the immune response of MenQuadfi® to serogroup C, one of the main se...
Source: marketscreener.com